Thursday, 14 May - Online Workshop Schedule
All session and presentation times are in the Pacific Time Zone and are subject to change. Each session day begins at 08:00, PDT (15:00, GMT/UTC).
Not certain how to convert times to your specific time zone; just click here.
Presenting author is underlined; presenters are subject to change.
| Thursday, 14 May 2020 | |
|---|---|
| 08:00 – 15:00 | |
| 08:00 | Welcome |
| 08:05 | Molecular & Genomic Diagnosis of Vascular Anomalies │ Thuy Phung (United States), Miikka Vikkula (Belgium) |
| Scientific Session 1 (08:40 - 09:40) | |
| Categories: Potpourri/Varied - a selection of the top scored oral abstracts | |
| 08:40 |
Role of RAS/MAPK pathway in a generalized lymphatic disorder responsive to MEK inhibitors │ Sarah Sheppard (United States), Michael March, Christoph Seiler, Dong Li, Leticia S Matsuoka, Mark Battig, Charlly Kao, Erin Pinto, Ian Krantz, Leslie Castelo-Soccio, Yoav Dori and Hakon Hakonarson |
| 08:48 |
Discovery and Characterization of RASopathy Mutations Underlying Lymphatic Anomalies and Preparation for Clinical Development │ Dong Li (United States), Michael March, Christoph Seiler, Erin Pinto, Leticia Matsuoka, Mark Battig, Sarah Sheppard, Charlly Kao, Tara Wenger, Jean Belasco, Yoav Dori and Hakon Hakonarson |
| 08:56 |
Identification of ANGPT2 Mutations as a Novel Cause of Primary Lymphedema │ Veli-Matti Leppänen, Pascal Brouillard, Emilia A. Korhonen, Tuomas Veli Sipilä, Sawan Kumar Jha, Nicole Revencu, Veerle Labarque, Elodie Fastre, Matthieu Schlogel, Marie Ravoet, Amihood Singer, Claudia Luzzatto, Donatella Angelone, Giovanni Crichiutti, Angela Valentina D'Elia, Jaakko Kuurne, Harri Elamaa, Gou Young Koh, Pipsa Saharinen, Kari Alitalo and Miikka Vikkula (Belgium) |
| 09:04 | Generation of a robust and clinically-relevant mouse model of Cerebral Cavernous Malformations │ Douglas Marchuk (United States) |
| 09:12 |
Need for an international pharmacovigilance system to improve safety associated to "off-label" and "off-evidence" drug use in vascular anomalies │ Niina Kleiber (Canada), Jérôme Coulombe, Laurence Gariépy-Assal, Josée Dubois, Catherine McCuaig, Julie Powell and Michèle David |
| 09:20 |
Genotype adjusted Variant Allele Fraction (GVAF), a novel metric correlating with clinical severity in 64 individuals with PIK3CA-associated lymphatic malformations │ Kaitlyn Zenner (United States), Chi Vicky Cheng, Dana Jensen, Andrew Timms, Giridhar Shivaram, Randall Bly, Sheila Ganti, Kathryn Whitlock, William Dobyns, Jonathan Perkins and James Bennett |
| 09:28 |
Cell free DNA from cyst fluid is a sensitive source for PIK3CA mutation detection in lymphatic malformations │ Kaitlyn Zenner (United States), Dana Jensen, Tori Cook, Randall Bly, Sheila Ganti, William Dobyns, Jonathan Perkins and James Bennett |
| Break - Non-CME Activity (09:40 - 09:55) | |
| Scientific Session 2 (09:55 - 11:15) | |
| Categories: Potpourri/Varied, Interventional Radiology, Quality-of-Life | |
| 09:55 (Difficult Case) |
RASA1 associated protein-losing enteropathy resulting in immune deficiency, hypercoaguability and malnutrition unresponsive to mTOR inhibition │ Elizabeth Nieman (United States), Melanie Fields, Megan Cooper, Viraine Weerasooriya, Maithilee Menezes, Mitchell Pet, Kamlesh Patel, Carlos Guevara, Marcia Willing, Denise Adams, Leonid Shmuylovich, Susan J. Bayliss and Christopher D. Malone |
| 10:05 (Difficult Case) | Fatal Lung Toxicity After Intralesional Bleomycin Sclerotherapy of a Vascular Malformation │ Alexander Cho, Sharon Kiang, William Tritch, Jonathan Lodenkamp and Roger Tomihama (United States) |
| 10:15 |
Utility of surveillance chest x-ray (CXR) and pulmonary function testing (PFT) in patients undergoing intralesional bleomycin in the treatment of vascular malformations │ Austin DeHart (United States), Joana Mack, Annsley Garner, Gresham Richter, Richard Nicholas, Kelly Stewart, Amber Smith, Spencer Lewis, and Shelley Crary |
| 10:23 |
Laboratory surveillance for intralesional bleomycin in the treatment of vascular malformations │ Joana Mack (United States), Austin DeHart, Bethany Verkamp, Gresham Richter, Kelly Stewart, Amber Smith, Spencer Lewis and Shelley Crary |
| 10:31 | 3D Imaging of Vascular Structure using Raster-Scanning Optoacoustic Mesoscopy │ Emily Geisler (United States), Jeyna K. Perez, James R. Seaward, Rami R. Hallac and Alex A. Kane |
| 10:39 |
Bleomycin Polidocanol Foam (BPF) stability: In vitro evidence for the effectiveness of a novel sclerotherapy for Venous Malformations │ Yi Sun (China), Hao Gu, Xi Yang, Ren Cai, Ying Shang, Li Hu, Yungying Wang, Hui Chen and Xiaoxi Lin |
| 10:47 |
Bleomycin Polidocanol Foam Sclerotherapy as a Novel Highly Efficient Technique for Venous Malformations: Clinical and laboratory studies │ Xi Yang (China), Hui Chen, Hao Gu, Yunbo Jin, Li Hu, Chen Hua, Yi Sun and Lin Xiaoxi |
| 10:55 |
Responsiveness of quality of life measures in patients with peripheral vascular malformations │ Max Lokhorst (The Netherlands), Sophie E.R. Horbach, Milton Waner, Teresa O, Carine Van der Vleuten, Lidwine B. Mokkink, Chantal M.A.M. van der Horst and Phyllis I. Spuls |
| 11:03 | Quality of life in children with congenital vascular malformations │ Frédérique Bouwman (The Netherlands), Ivo de Blaauw, Maroeska te Loo, Willemijn Klein, Leo Schultze Kool, Carine Van der Vleuten, Bas Verhoeven and Sanne Botden |
| Break - Non-CME Session (11:15 - 11:45) | |
| Scientific Session 3 (11:45 - 13:15) | |
| Category: Lymphatic | |
| 11:45 |
Dissecting the relationship between genotype and therapeutic responses in generalized lymphatic anomalies │ Ajit Muley, Kate Stanley, Jessica Giordano, Jessica Kandel, Russell Miller, Vimla Aggarwal, Ron Wapner, David Goldstein, June Wu and Carrie Shawber (United States) |
| 11:52 | Primary, Non-Syndromic Lymphedema: Clinical Features and Predictors of Severity │ Nancy Duan (Canada), Kim Durlacher, Wendy Moss, Kathryn V. Isaac and Jugpal S. Arneja |
| 11:59 |
Evaluation of Clinical and Radiographic Response of Patients with Complex Lymphatic Anomalies with Bone Involvement Treated with Sirolimus and Bisphosphonates │ Richard P. Greiwe (United States), Wendy London, Paige Kao, Yaser Diab, Ionela Iacobas, Karen Fernandez, Kristen Snyder, Sherry Bayliff, Gulraiz Chaudry, Cameron Trenor and Denise Adams |
| 12:06 |
Radiologic Features of Bone Lesions in Complicated Lymphatic Anomalies │ Richard P. Greiwe, Raja Shaikh, Sudhen B. Desai, Wendy London, Yaser Diab, Ionela Iacobas, Karen Fernandez, Kristen Snyder, Sherry Bayliff, Cameron Trenor, Denise Adams and Gulraiz Chaudry (United States) |
| 12:13 |
Lymphatic embolization of abnormal pulmonary lymphatic flow in patients with lymphatic malformations │ Maxim Itkin (United States), Leo Mascarenhas, Gregory Nadolski and Deborah Rabinowitz |
| 12:20 |
Delaying Invasive Head and Neck Lymphatic Malformation Treatment Improves Outcomes │ Juliana Bonilla-Velez (United States), Kathryn B. Whitlock, Sheila Ganti, Randall Bly, John P. Dahl, Scott Manning and Jonathan Perkins |
| 12:27 |
Somatic PIK3CA Mutation underlies both Micro- and Macrocystic Lymphatic Malformation │ Ines Martinez-Corral, , Yan Zhang, Milena Petkova, Henrik Ortsäter, Sofie Sjöberg, Sandra D. Castillo, Pascal Brouillard, Louis Libbrecht, Dieter Saur, Mariona Graupera, Kari Alitalo, Laurence Boon, Miikka Vikkula (Belgium) and Taija Mäkinen |
| 12:34 |
MR Lymphangiography Findings in Patients with KLA and GSD │ Yoav Dori (United States), Chris Smith, Ganesh Krishnamurthy, Fernando Escobar, Abhay Srinivasan, David Biko, Jordan Rapp, Jean Belasco, Hakon Hakonarson, Jessica Foster and Kristen Snyder |
| 12:41 |
Outcome of MEK Inhibition of RAS-MAPK Pathway in Patients with Severe Lymphatic Disorders and RAS-MAPK Gene Defects │ Yoav Dori (United States), Jessica Foster, Denise Adams, Jean Belasco, Kristen Snyder, Dong Li and Hakon Hakonarson |
| 12:48 |
Antenatal rapamycin therapy for a rapidly enlarging fetal mixed cystic lymphatic neck malformation causing polyhydramnios │ Joel Livingston (Canada), Nouf Alrowaily, Manuel Carcao, Paolo Campisi, Sebastian Ranguis, Philip John and Greg Ryan |
| 12:55 | Clinical Implications of Lymph Loss in Complicated Lymphatic Anomalies │ Ionela Iacobas (United States), Meghan O'Hare, Priya Mahajan, Judith F Margolin, Darla Espinoza and Cameron Trenor |
| 13:02 |
Longitudinal Changes in Plasma Biomarkers in Patient with Kaposiform Lymphangiomatosis Treated with Sirolimus and Adjunctive Zoledronate │ Janet Crane, Jackie Manfredo, Clifford Takemoto, Elisa Boscolo, Denise Adams and and Timothy Le Cras (United States) |
| Break - Non-CME Activity (13:15 - 13:30) | |
| Scientific Session 4 (13:30- 14:30) | |
| Categories: Lymphatic, Quality-of-Life, Potpourri/Varied | |
| 13:30 |
MicroRNA-21 is upregulated in human lymphatic malformation endothelial cells and drives endothelial cell proliferation through hyperphosphorylation of MAPK/ERK │ Graham Strub (United States), Haihong Zhang, Gresham Richter and Hayden Bowman |
| 13:37 |
Finalizing the international core domain set for peripheral vascular malformations: The OVAMA project │ Max Lokhorst (The Netherlands), Sophie E.R. Horbach, Chantal M.A.M. van der Horst, Phyllis I. Spuls and OVAMA steering group |
| 13:43 |
The European Reference Network (ERN) for Rare Vascular Diseases (VASCERN): VASCA-Working Group - towards Better Management of Vascular Anomaly Patients │ Miikka Vikkula (Belgium), Leo Schultze Kool, Alan Irvine, Päivi Salminen, Nader Ghaffarpour, Andrea Diociaiuti, Jochen Rössler, Caroline van den Bosch, Eulalia Baselga, Anne Dompmartin and Laurence Boon |
| 13:49 |
Patient and Family Reported Quality of Life Outcomes in Children with Low Flow Vascular Malformations │ Rachel Swerdlin (United States), Allyson Wright, Anne Gill, Michael Briones, Jonathan Meisel, Steven Goudy and C. Matthew Hawkins |
| 13:55 |
Multidisciplinary Approaches to Vascular Anomalies (MAVA): An International Educational Webinar Series │ Taizo Nakano (United States), Lauren Hill, Lauren Larroque, The Hendren Project and Ann M. Kulungowski |
| 14:01 | Imatinib monotherapy in three patients with PDGFRB Activating Variant Spectrum Disorder │ Tara Wenger (United States), Randall Bly, Jonathan Perkins, Markus Boos, Natalie Wu, Catherine Albert, Shireen Ganapathi, John Dahl and William Dobyns |
| 14:07 |
A New Model of Assessment, Evaluation and Reporting of the Outcome Measures After Endovascular Therapy of Slow-flow Vascular Malformations: A Preliminary Report on 21 Patients from a Nordic Tertiary Care Center │ Arindam Bharadwaz (Denmark) |
| 14:13 |
Using Artificial Intelligence (AI) to develop a novel Vascular Anomalies Severity Score (VASS) for the head and neck │ Salim Afshar (United States) |
| ISSVA General Assembly (14:30- 15:00) | |